n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide and Dermatitis--Atopic

n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide has been researched along with Dermatitis--Atopic* in 2 studies

Other Studies

2 other study(ies) available for n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide and Dermatitis--Atopic

Article	Year
CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3. Biochemical genetics, 2021, Volume: 59, Issue:2 Atopic dermatitis (AD) is a chronic inflammatory skin disease influencing not only children but also adults. It is well-known that AD has a complex pathogenesis without effective therapy. Herein, we explored the function and mechanism of CYT387, a novel JAK2 inhibitor, on epidermal barrier damage. HaCaT cells exposed with high-concentration Ca Topics: Benzamides; Cell Line, Transformed; Dermatitis, Atopic; Epidermis; Filaggrin Proteins; Humans; Interleukin-13; Interleukin-13 Receptor alpha1 Subunit; Janus Kinase 2; MicroRNAs; Pyrimidines; STAT3 Transcription Factor	2021
Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice. International journal of molecular sciences, 2018, Dec-10, Volume: 19, Issue:12 Atopic dermatitis (AD) is a chronic recurrent skin disease dominated by T-helper 2 inflammation. Momelotinib (MMB) is a novel JAK1/JAK2 inhibitor suppressing the signal transduction of multiple pro-inflammatory cytokines. Recent studies indicated that JAK inhibitor could play a therapeutic role in AD disease. In this study, we evaluated the efficacy of MMB as a novel JAK1/JAK2 inhibitor in DNCB-induced AD mice and TSLP-activated dendritic cells. Our data showed that topical application of MMB reduced the skin severity scores and total serum IgE levels, and alleviated the histological indexes including epidermal thickness measurement and mast cell number. Also, it was demonstrated that MMB down-regulated the mRNA expression of IL-4, IL-5, IFN-γ and TSLP, and inhibited the phosphorylation of STAT1, STAT3 and STAT5 in skin lesions. Moreover, MMB reduced the expression of CD80, CD86, MHCII and mRNA of OX40L in TSLP-activated dendritic cells. In general, our study suggests that MMB can improve the symptoms of AD and topical application of MMB can become a promising new therapy strategy for AD. Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Benzamides; Cytokines; Dendritic Cells; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Models, Animal; Female; Gene Expression Regulation; Immunoglobulin E; Janus Kinase 1; Janus Kinase 2; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; OX40 Ligand; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Skin; STAT Transcription Factors; Thymic Stromal Lymphopoietin	2018

Article

Year

CYT387, a Novel JAK2 Inhibitor, Suppresses IL-13-Induced Epidermal Barrier Dysfunction Via miR-143 Targeting IL-13Rα1 and STAT3.

Biochemical genetics, 2021, Volume: 59, Issue:2

Atopic dermatitis (AD) is a chronic inflammatory skin disease influencing not only children but also adults. It is well-known that AD has a complex pathogenesis without effective therapy. Herein, we explored the function and mechanism of CYT387, a novel JAK2 inhibitor, on epidermal barrier damage. HaCaT cells exposed with high-concentration Ca

Topics: Benzamides; Cell Line, Transformed; Dermatitis, Atopic; Epidermis; Filaggrin Proteins; Humans; Interleukin-13; Interleukin-13 Receptor alpha1 Subunit; Janus Kinase 2; MicroRNAs; Pyrimidines; STAT3 Transcription Factor

2021

Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.

International journal of molecular sciences, 2018, Dec-10, Volume: 19, Issue:12

Atopic dermatitis (AD) is a chronic recurrent skin disease dominated by T-helper 2 inflammation. Momelotinib (MMB) is a novel JAK1/JAK2 inhibitor suppressing the signal transduction of multiple pro-inflammatory cytokines. Recent studies indicated that JAK inhibitor could play a therapeutic role in AD disease. In this study, we evaluated the efficacy of MMB as a novel JAK1/JAK2 inhibitor in DNCB-induced AD mice and TSLP-activated dendritic cells. Our data showed that topical application of MMB reduced the skin severity scores and total serum IgE levels, and alleviated the histological indexes including epidermal thickness measurement and mast cell number. Also, it was demonstrated that MMB down-regulated the mRNA expression of IL-4, IL-5, IFN-γ and TSLP, and inhibited the phosphorylation of STAT1, STAT3 and STAT5 in skin lesions. Moreover, MMB reduced the expression of CD80, CD86, MHCII and mRNA of OX40L in TSLP-activated dendritic cells. In general, our study suggests that MMB can improve the symptoms of AD and topical application of MMB can become a promising new therapy strategy for AD.

Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Benzamides; Cytokines; Dendritic Cells; Dermatitis, Atopic; Dinitrochlorobenzene; Disease Models, Animal; Female; Gene Expression Regulation; Immunoglobulin E; Janus Kinase 1; Janus Kinase 2; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; OX40 Ligand; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; RNA, Messenger; Skin; STAT Transcription Factors; Thymic Stromal Lymphopoietin

2018